Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biomaven who wrote (4303)	6/7/2016 2:32:00 PM
From: tktom	Read Replies (1) \| Respond to of 4474

Yes, Criz is currently the only approved first line agent for ALK+, which is why it is the comparator against briga in the new front line trial.But alectinib will get front line approval before that trial is fully enrolled, and so it will be hard to get people to enroll in a trial where they might end up with the much inferior (criz) drug. The path that Ariad unfortunately took was to push the dose to 240 mg to try to capture both EGFR and ALK+ at the one dose, losing 18 months in the process, and finally conceding that EGFR wasn't going to work. If they would have separated those trials, Brigatinib for ALK+ would be approved by now..